A Phase II, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of IMVAMUNE(R) Using Three Immunization Schedules and Two Modes of Delivery
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2016
Price : $35 *
At a glance
- Drugs Smallpox vaccine (Primary)
- Indications Smallpox
- Focus Adverse reactions; Pharmacodynamics
- 21 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Dec 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
- 18 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.